Abstract
Introduction
Despite progress, HIV is still a major public health threat with over 75 million deaths, 2 million infections a year and over 1 million HIV-associated TB cases a year 1, 2 . The impact of the HIV epidemic prompted an unprecedented response and we now know more about HIV than any other pathogen in history. The discovery of effective antiretroviral treatment (ART) in 1996 and subsequent evidence regarding the prevention of illness, death and transmission transformed the epidemic from an unending, unmitigated disaster into something that could be prevented and even ended someday [3] [4] [5] [6] [7] [8] [9] 10 . The potential for expanded access to ART to curb the epidemic and the concept of treatment as prevention was introduced in 2006 5 and later formalized by the World Health Organization (WHO) 11 . Over the past decade, the global and local HIV strategy has
shifted from "test-and-wait" to "test-and-treat" focusing on achieving the 90-90-90 target (73% of people on ART and virally suppressed) and ending AIDS (defined as universal treatment with less than one AIDS case and one AIDS related death per 1000 population) 12 13, 14 .
Policy discussions around treatment-as-prevention have focused on how to increase access to testing and how early to provide diagnosis and treatment. Global HIV leaders and stakeholders turned to modeling to answer key questions about the risks and benefits of expanding access to treatment. Before and after the prevention impact of ART was understood, researchers used models to explore the impact of possible ART expansion scenarios [15] [16] [17] [18] [19] . While a few models explored expansion of ART access beyond existing WHO guidelines, most models limited testing and treatment to those who were severely immunocompromised 19 . Similarly, traditional costing efforts could be classified as "doomsday costing" insofar as they took a health sector perspective and only looked at the costs of providing earlier treatment while ignoring the potential prevention benefits and cost savings of earlier treatment 20, 21 . More modern "second generation" approaches to economic modeling took into account the prevention impact of scaling up treatment along with other interventions 18, [22] [23] [24] . These models explored treatment as prevention of illness, death, and transmission. In some cases, the models were combined with a costing framework to examine the costs, cost benefits, and costs savings of various scale-up scenarios [22] [23] [24] [25] . The dominant model (GOALS) used by the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Global Fund and the United States government and many countries now includes the prevention impact of ART and is used to determine the health and transmission impact, costs and cost-savings for various HIV response scenarios 23 . The UNAIDS estimates uses GOALS that incorporates data from available surveys and other surveillance information and makes forward projections of incidence, prevalence and resources needs according to their financial framework categories 23 . In the 2016 the UNAIDS HIV Update and in the UNAIDS resource needs projections, the incidence and prevalence were reported as being stable for the 5 years from 2010 to 2015 in all regions of the world except for Eastern Europe where the rates were increasing 1, 23 . During this time the world spent an estimated US$200 Bn on attempting to control HIV and the conclusion that can be drawn from the report is that the significant investment has had little or no impact on incidence or mortality. If true, this has major implications for future resource needs as well as for global HIV control strategy since the impact of treatment appears to be far less than expected. However, there are reasons to question the flat-line UNAIDS estimates of incidence and prevalence as these results contrast with other models and the scientific evidence regarding the potential impact of ART and other prevention interventions. Recent population-based studies from a number of countries suggest a marked decline in incidence, prevalence and deaths, mostly likely due to treatment expansion, in many countries in East and Southern Africa 26 .
Methods
The marked contrast in model outcomes, one predicting flat-line incidence and prevalence in four of five regions 1, 23 while others projecting a steady decline to elimination, prompted us to explore the importance of ART efficacy, effectiveness and coverage parameters. Specifically, for 2015
and 2016, we reviewed global and national mathematical modeling studies that looked at impact of ART (with or without other HIV prevention interventions) or 90-90-90 on either new HIV infections or investment or both. We reviewed these HIV epidemiologic and costing models for their structure and parameterization around ART. Table 1 describes the 9 models, including the available parameters used to derive ART effectiveness expressed in terms of percentage reduction in HIV transmission. The modeling parameters for ART effectiveness by 2020 ranged from 20% to 86% for ART effectiveness.
Results
This disparity in ART Effectiveness is further highlighted in Figure what parameters to use and how they are applied to the epidemiology and costing is critical when using models to guide the HIV response. Our brief review suggests that many of the current models have likely underestimated the impact of ART. This overly conservative assessment could account for past decisions to under invest in expanding access to treatment while using remaining resources for other budget categories 27 . Using more realistic parameters around ART suggests that as we expand access and support the achievement of sustainable viral suppression it will be possible to significantly reduce transmission and eliminate HIV in many settings. 
